Advanced Practice Providers Oncology Summit.

Revolutionizing Leukemia Treatment: Allogeneic Transplants, Engineered T Cell Therapy, and Navigating the Complexities of GVHD

Overview

Participants will explore cutting-edge therapies in leukemia treatment, including allogeneic transplants’ potential to trigger immune-mediated responses against leukemia. The session will also dive into the complexities of managing and preventing acute and chronic graft-versus-host disease (GVHD) and the challenges they post in patient care.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Discuss the potential of an allogeneic transplant to mount an immune-mediated attack against leukemia in the recipient

2. Identify concepts behind engineered T cell therapy, and for what diseases are commercial CAR-T cells active

3. Describe challenges to the management and prevention of acute and chronic GVHD

Faculty: Gary Schiller, MD, FACP

Credit Hours: CREDIT HOURS: 1.00 AMA PRA Category 1 Credit™ 1.00 ANCC

Course Expires: 4.19.2025

Similar Courses To Consider

Melanoma Management in 2024

Advanced Practice Providers Oncology Summit. ONCOLOGY ON DEMAND LIBRARY Melanoma Management in 2024 Overview This program offers a focused exploration of the standard guidelines and best practices

VIEW COURSE »